

The Impact of Viral Conjunctivitis (Eye Flu) On Public Health: Causes, Symptoms, And Prevention

Mohd Niyaz Alam¹, Tilotma Sahu²

¹Student, Rungta Institute of Pharmaceutical Sciences, kohka (C.G), Rungta Institute of Pharmaceutical Sciences and Research (C G), India.

²Associate Professor, Rungta Institute of Pharmaceutical Sciences, kohka (C.G), Rungta Institute of Pharmaceutical Sciences and Research (C G), India.

Corresponding Author: tilu06sahu@gmail.com

Abstract— Conjunctivitis, often colloquially referred to as "Red eye," is a common eye condition characterized by inflammation of the conjunctiva, the thin membrane covering the white part of the eye and inner eyelids. This inflammation can result from various causes, including viral, bacterial, allergic, or irritant triggers. Of particular interest is viral conjunctivitis, which is sometimes informally termed "eye flu" due to its association with viral infections resembling symptoms of the flu. Common symptoms of viral conjunctivitis include redness, watery discharge, itching, eyelid swelling, and light sensitivity. Effective management of viral conjunctivitis primarily involves symptom relief and the prevention of transmission. Hygiene measures, such as frequent handwashing and avoiding eye touching, are crucial in limiting the spread of the virus. Lubricating eye drops can alleviate dryness and discomfort, while cold compresses can reduce swelling and irritation. Additionally, individuals with viral conjunctivitis should avoid close contact with others and abstain from sharing personal items to prevent contagion. The research emphasizes various legal frameworks, focusing on the regulation of emerging technology usage, the protection of users and innovators, and the support of innovation by harnessing the potential of emerging technologies. It also highlights the efforts of national agencies and their sub-agencies in ensuring the implementation of these legal frameworks and the execution of various programs aimed at advancing the innovation of emerging technologies. These initiatives serve to support developers and industries while upholding the security and safety of users. Overall, this underlines the nation's unwavering commitment to Antiviral eye drops may be prescribed in severe or persistent cases. Typically, viral conjunctivitis resolves spontaneously within one to two weeks. For proper diagnosis and guidance on treatment, it is advisable to seek consultation with a healthcare professional, particularly in cases of severe or recurrent conjunctivitis accompanied by concerning symptoms.

Index Terms— Viral conjunctivitis, Eye infection, Inflammation of the eye Contagious eye condition, Eye redness.

1. Introduction

Conjunctivitis is characterized by inflammation and lump of the conjunctival kerchief, accompanied by engorgement of the blood vessels, optic discharge, and pain. multitudinous subjects are affected with conjunctivitis worldwide, and it's one of the most frequent reasons for office visits to general medical and

ophthalmology conventions. further than 80 of all acute cases of conjunctivitis are reported to be diagnosed by non-ophthalmologists including internists, family medicine croakers, pediatricians, and nurse practitioners. (1) This imposes a great profitable burden to the healthcare system and occupies a great proportion of the office visits in multitudinous medical specialties. It's estimated that the cost of treating bacterial conjunctivitis is \$ 857 million annually in the United States alone. (2)

It has been reported that nearly 60 of all cases with acute conjunctivitis admit antibiotic eye drops; and the vast majority admit their tradition from a non- ophthalmologist croaker. For illustration, 68 of cases who visited a croaker at an emergency room entered antibiotic eye drops while this figure dropped to 36 for those who saw an ophthalmologist. (1) Interestingly, cases from a advanced socioeconomic status were more likely to admit and fill a tradition for their conjunctivitis. (1)

There are several ways to classify conjunctivitis; it may be classified predicated on etiology, chronicity, strictness, and extend of involvement of the girding kerchief. The etiology of conjunctivitis may be contagious or non- contagious. Viral conjunctivitis followed by bacterial conjunctivitis is the most common cause of contagious conjunctivitis, while antipathetic and bane- induced conjunctivitis are among the most common non- contagious etiologies. In terms of chronicity, conjunctivitis may be divided into acute with rapid-fire- fire onset and duration of four weeks or lower, subacute, and habitual with duration longer than four weeks.

Manuscript revised November 17, 2023; accepted November 18, 2023. Date of publication November 20, 2023.

This paper available online at www.ijprse.com
ISSN (Online): 2582-7898; SJIF: 5.59

Table 1
Guideline to help differentiate the major etiologies in conjunctivitis

Clinical history and exam findings	Most probable etiologies
Alarming signs and symptoms	
Decreased vision, severe pain, painful pupillary reaction, anisocoria, orbital signs	Uveitis, scleritis, keratitis, glaucoma, orbital, or parasellar pathology
Chronicity	
Sudden onset, lasting less than four weeks	Infectious conjunctivitis, allergic conjunctivitis, acute systemic reactions (SJS/TEN)
Insidious onset, chronic course	Conjunctivitis associated with systemic diseases, toxic conjunctivitis, allergic conjunctivitis
Recurrent course	Allergic conjunctivitis, conjunctivitis associated with systemic diseases
Associated symptoms	
Skin lesions, arthropathy, genito-perineal involvement, oropharyngeal lesions	Conjunctivitis associated with systemic diseases, infectious diseases
Drug history	
Long-term eye drop usage	Toxic conjunctivitis, allergic conjunctivitis
Recent initiation of a systemic medication	Acute systemic reactions (SJS/TEN)
SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis	

Table 2

Selected non-conjunctivitis etiologies of red eye

Differential diagnosis	Symptoms	Exam findings
Dry eyes	Burning and FB sensation. Symptoms are usually transient, worse with reading or watching TV due to decreased blinking. Symptoms are worse in dry, cold, and windy environments due to increased evaporation	Bilateral redness, superficial punctate keratopathy, meibomian glands dysfunction, decreased tear break-up time, small tear meniscus
Blepharitis	Similar to dry eyes	Redness greater at the margins of eyelids, inflammation, telangiectasia, and crust around eyelashes
Pterygium	Recurrent ocular redness	Visible conjunctival extension over the cornea
Hordeolum, chalazion	Eyelid pain and swelling	Palpable eyelid mass, may be tender or not
Anterior segment tumors	Variable	Variable
Corneal abrasion, keratitis, corneal foreign body	FB sensation, relevant history including contact lens usage and occupational exposure	Corneal epithelial defects, corneal infiltration, corneal FB
Contact lens overwear	Relevant history	Corneal epithelial defect
Subconjunctival hemorrhage	Ocular redness	Blood under conjunctiva
Scleritis	Decreased vision, moderate to severe pain	Redness, bluish scleral hue
Iritis	Photophobia, pain, blurred vision. Symptoms are usually bilateral	Decreased vision, poorly reacting pupils, constant eye pain radiating to temple and brow. Redness, severe photophobia, presence of inflammatory cells in the anterior chamber
Angle closure glaucoma	Headaches, nausea, vomiting, ocular pain, decreased vision, light sensitivity, and seeing haloes around lights. Symptoms are usually unilateral.	Firm eye upon palpation, ocular redness with limbal injection. Appearance of a hazy/steamy cornea, moderately dilated pupils that are unreactive to light.
Carotid cavernous fistula	Chronic red eye, may have a history of head trauma	Dilated tortuous vessels (corkscrew vessels), bruits upon auscultation with a stethoscope
Endophthalmitis	Severe pain, photophobia, may have a history of eye surgery or ocular trauma	Redness, puss in the anterior chamber and photophobia
Cellulitis	Pain, double vision, and fullness	Redness and swelling of lids, may have restriction of the eye movements, may have a history of preceding sinusitis (usually ethmoiditis)

FB, foreign body; TV, television

(3) likewise, conjunctivitis may be labeled as severe when the affected individualities are extremely characteristic and there is a cornucopia of mucopurulent discharge. Conjunctivitis may be associated with the involvement of the girding kerchief analogous as the eyelid peripheries and cornea in blepharconjunctivitis and viral keratoconjunctivitis, singly.

also, conjunctivitis may be associated with systemic conditions, including vulnerable- related conditions (e.g., Reiter's, Stevens- Johnson pattern (SJS), and keratoconjunctivitis sicca in rheumatoid arthritis), nutritional deprivation (vitamin A insufficiency), and natural metabolic runs (Richner- Hanhart pattern and porphyria) (4,5).

It's extremely important to separate conjunctivitis from other causes of "red eye" associated with severe sight- or life-hanging consequences similar as acute angle check glaucoma, uveitis, endophthalmitis, carotid- cavernous fistula, cellulitis, and anterior member excrescences.

2. History And Clinical Examination

A. How to diagnose conjunctivitis

Conjunctival injection or "red eye" is a participated donation for numerous ophthalmic conditions, and it accounts for over to 1 of all primary care office visits.(6) The clinicians, whether ophthalmologist or not, must be alive that " red eye " may be the presenting sign for serious eye conditions similar as uveitis, keratitis, or scleritis, or it may be secondary to further benign conditions that are limited just to the conjunctival kerchief(e.g., conjunctivitis or subconjunctival hemorrhage). Traditionally, it was believed that further dangerous ophthalmic conditions are associated with disturbances in vision, disabling pain, and photophobia. (6) still, in a recent large meta- analysis, (6) anisocoria and mild photophobia were significantly associated with "serious eye conditions"; the presence of these two signs could discover 59 of cases of "serious eye conditions", including anterior uveitis and keratitis. Table 2 provides a summary of the main etiologies of "red eye" and their clinical characteristics.

B. How to distinguish infectious conjunctivitis from non-infectious conjunctivitis

Carrying history from cases who present with conjunctivitis is pivotal in order to arrive at the correct opinion. A focused optical history should include the following onset and duration of symptoms; laterality; impairment of vision; presence of itching; contact lens wear and tear history; presence of fellow trippers

similar as recent upper respiratory infection, sinusitis, and lymphadenopathy; former occurrences of conjunctivitis; systemic disinclinations and drug; and history of exposure to chemical agents.

The presence of indigenous signs similar as fever, malaise, fatigue, and contact with individualities with conjunctivitis helps to further constrict down the discriminational opinion. Physical examination, including checking for palpable lymph

bumps, especially in the periauricular and submandibular areas, is of great significance. Ophthalmic examination should be performed to determine the type of discharge. Closer examination using a tear- beacon biomicroscope to estimate the optical face structures including the palpebral conjunctiva for the presence of pseudomembranes, symblepharon, papilla or follicles, and the corneal towel for the presence of darkness and infiltrates is absolutely essential.

Some of the clinical signs and symptoms that are used to help diagnose contagious conjunctivitis include the following eye discharge, conjunctival injection, presence of red eye(s), eyelashes being stuck together in the morning, grit of the eye(s), eyelid or conjunctival edema, and history of contact with individualities with conjunctivitis. (7)

Antipathetic conjunctivitis may be underdiagnosed and undertreated. (8) It's presented with itching, chemosis, and greenishness in the absence of any significant corneal involvement. (9) The degree of conjunctival lump is frequently out of proportion to conjunctival hyperemia. The main findings in vernal keratoconjunctivitis (VKC) are the presence of giant papillae in the superior tarsal conjunctiva accompanied by severe itching, (10) while the presence of conjunctival scar and anterior subcapsular cataract supports the opinion of atopic keratoconjunctivitis (AKC). (11)

Another analogous condition, habitual poisonous conjunctivitis, may present with watery discharge, an original papillary conjunctival response followed by a follicular response, punctate epithelial corrosion of the cornea, and eyelid dermatitis. (12,13,14)

C. How to distinguish bacterial conjunctivitis from viral conjunctivitis

Predicting the underpinning etiology of conjunctivitis grounded on the presenting signs and symptoms may frequently affect in an inaccurate opinion. In one study, centers with moxie in optical face complaint had a delicacy rate of only 48 in making the correct opinion of adenoviral conjunctivitis. (15) Several other studies demonstrated that bacterial pathogens are only insulated in 50 of cases of suspected bacterial conjunctivitis. (16) In addition, one study reported that over to 52 of presumed cases of viral conjunctivitis were culture-positive for bacteria. (15)

Traditionally, the following associations between the clinical history and the etiology of conjunctivitis were believed to be true; these principles were presented in numerous handbooks and were used to elect cases in numerous clinical trials.(17) For illustration, according to the major textbook books in ophthalmology(e.g., Krachmer, Duane, and Kanski), involvement of one eye followed by the involvement of the alternate eye within 24 – 48 hours is reflective of bacterial infection, while if the alternate eye becomes infected after 48 hours with an accompanying enlarged periauricular lymph knot, a viral etiology should be considered. According to the same handbooks, a papillary conjunctival response or pseudomembranous conjunctivitis explosively suggests a

bacterial origin for conjunctivitis while follicular conjunctival response is more likely to indicate a viral etiology.

There are numerous other associations between the etiology of conjunctivitis and symptoms that are allowed to be true, but warrant strong clinical substantiation. For illustration, association between lack of itching and bacterial conjunctivitis have come under scrutiny in the recent times. Other associations that formerly allowed to be true but warrant substantiation include recent upper respiratory tract infection and lymphadenopathy in favor of viral conjunctivitis; sinusitis, fever, malaise, and fatigue in association with bacterial conjunctivitis; and former history of conjunctivitis with bilateral involvement of the eyes in favor of viral and antipathetic but not bacterial conjunctivitis.

A meta- analysis in 2003 failed to find any clinical studies relating the signs and symptoms of conjunctivitis with its underpinning etiology.(17) Following the below meta-analysis, a prospective study was conducted and set up that combination of three signs, bilateral matting of the eyelids, lack of itching, and no former history of conjunctivitis were strong predictors of bacterial conjunctivitis.(18) Having both eyes matter and their eyelashes cleave together in the morning was a stronger predictor for positive bacterial culture, and either itching or a former occasion of conjunctivitis made a positive bacterial culture less likely. In addition, types of the discharge (purulent, mucus, or watery) or other symptoms weren't specific to any particular class of conjunctivitis.

A more recent meta- analysis, which anatomized the clinical data of 622 cases from three clinical trials, (19) set up that cases with purulent discharge or mild to moderate red eye were less likely to profit from topical antibiotics; this chancing reiterates lack of meaningful correlation between signs and symptoms and the underpinning etiology in utmost cases of conjunctivitis. Another recent study in 2013 set up a strong liability of positive bacterial culture results in cases with the “unsticking of the eyelids” upon waking up in the morning, and the age above 50 at donation. (20)

D. How do laboratory findings help us?

Clinicians may collect discharge samples from eyes with conjunctivitis and shoot them for microbiological evaluation. Conjunctival societies are generally reserved for cases of suspected contagious neonatal conjunctivitis, intermittent conjunctivitis, conjunctivitis recalcitrant to remedy, conjunctivitis presenting with severe purulent discharge, and cases suspicious for gonococcal or chlamydial infection. (21) hearties from the discharge are better to be taken before the inauguration of antimicrobial remedy. The hearties are also plated in colorful growth mediums in the laboratory for carrying societies. Sabouraud agar plates are used to identify fungus, and it should be employed in cases with habitual blepharitis and those who are immunocompromised. Anaerobic culture plates may also be helpful, especially in cases with a history of former surgery or trauma. (22) If antimicrobial remedy has formerly been started, they should be stopped 48 hours prior to carrying

societies. In a five- time review of 138 pediatric optical face infections, the most common organisms were coagulase-negative staphylococci, followed by *Pseudomonas aeruginosa* and *Staphylococcus aureus*. (23)

Nucleic acid modification ways, taking special hearties, may be used in diagnosing viral infections, where a multitude of polymerase chain response (PCR) tests for discovery of contagions are available.

Although primary studies from in- office rapid-fire antigen testing for adenoviruses report 89 perceptivity and up to 94 particularities, (21) the results of more recent studies point toward a high particularity but only moderate perceptivity ranging from 39.5 to 50. (24) Consequently, it may be suggested that negative Adeno- Plus test results should be verified by real- time PCR owing to its sour perceptivity.

For those suspected of having antipathetic conjunctivitis, skin scrape test or intradermal injection of common allergens, and assays for detecting elevated in vitro situations of specific serum IgE may be used; still, the opinion of antipathetic conjunctivitis remains a clinical bone

E. Viral conjunctivitis

Viral conjunctivitis is the most common overall cause of contagious conjunctivitis, and it's generally secondary to inoculation of the optical face with the adenoviruses. (25,26) Less constantly, other contagions may be the underpinning etiology in viral conjunctivitis; amongst them, herpes simplex contagion (HSV), varicella zoster virus (VZV), and enterovirus have been the subject of investigation. (27)

F. Adenoviral conjunctivitis

As the leading cause of contagious conjunctivitis worldwide, up to 90 of viral conjunctivitis cases are caused by adenoviruses. (28) Recent advances in genome sequencing of mortal adenoviruses (HAdV) have linked over 72 unique HAdV genotypes classified into seven different species (HAdV- A through HAdV- G), with HAdV- D species having the most members and the strongest association with viral conjunctivitis.(29,30).

perhaps the most common form of infection by the adenoviruses in children is pharyngoconjunctival fever (PCF) caused by HAdV types 3, 4, and 7. (31) This condition is generally characterized by the presence of fever, pharyngitis, periauricular lymphadenopathy, and perceptive follicular conjunctivitis. fresh optic face findings include edema, hyperemia, and petechial hemorrhages of the conjunctiva as a result of commerce between pro- seditious cytokines and conjunctival vasculature. (32) This condition is tone- limited, constantly resolving spontaneously in two – three weeks without any treatment.

The most severe optic manifestation of adenoviral infection is the epidemic keratoconjunctivitis (EKC); this condition affects both the conjunctiva and cornea, leaving ahead long- lasting and endless optic face changes and visual disturbances. optic manifestations of EKC include conjunctival discharge,

follicular conjunctivitis, corneal subepithelial infiltrates (SEI), corneal scarring, development of conjunctival membranes and pseudomembranes, and symblepharon conformation (figures 1 and 2).



Fig.1. Adenoviral conjunctivitis presenting as bilateral watery eyes.



Fig.2. Pseudomembrane formation in a patient with adenoviral conjunctivitis.




Fig.3. Subepithelial infiltrations in a patient with adenoviral conjunctivitis.

Classically, serotypes 8, 19, 37, and less constantly serotype 4 were believed to be associated with EKC, but more lately, HAdV- D53 and HAdV- D54 have been linked in several outbreaks and are allowed to be responsible for the maturity of EKC cases. (30).

Pseudomembranes, which are wastes of fibrin-rich exudates without blood or lymphatic vessels, may be encountered in the tarsal conjunctiva of the EKC cases. (35) Depending on the intensity of inflammation, real conjunctival membranes may also form in EKC. True membranes, formerly form, can lead to the development of subepithelial fibrosis and symblepharon; also, they tend to bleed oppressively upon junking. (36).

Cornea is another towel that may come negatively affected in EKC. Replication of the contagion in the corneal epithelium may beget superficial punctate keratopathy, followed by focal areas of epithelial darkness. (37) Focal SEI in the anterior stroma of the cornea appears roughly 7 – 10 days following the original involvement of the eyes with EKC (38) (Figure 3). This darkness may persist for times, and they may be associated with visual disturbance, photophobia, and presbyopia. The prevalence of SEI conformation in EKC has been reported to vary from 49.1 to 80. (39) An immunologic response to the replicating adenoviruses in anterior stromal keratocytes is hypothecated to be the beginning medium for the conformation of SEIs. The observation that this darkness reoccur following termination of steroids supports the thesis. (40).

Adenovirus conjunctivitis is veritably contagious and it may be transmitted up to 50 of the time according to some reports.(41,42) The contagion may spread through polluted fritters, medical bias, polluted water at the swimming pools, or by sharing of particular particulars; as numerous as 46 of individualities with viral conjunctivitis had positive viral culture grown from their hands according to one study.(43) The adenovirus is a veritably hardy organism, and it's reported to be resistant to 70 isopropyl alcohol and 3 hydrogen peroxide.(44) The American Academy of Ophthalmology recommends using a 110 dilute bleach result(sodium hypochlorite) to disinfect the office outfit and instruments against common contagious agents encountered in eye care conventions including the adenoviruses.(45)

Due to the largely contagious nature of viral conjunctivitis, frequent hand washing, scrupulous disinfection of medical instruments, and insulation of conjunctivitis cases from the rest in the healthcare provider's office has been recommended. (46) The incubation period for the adenovirus is roughly 5 – 12 days, while the infected individualities can transmit the complaint for over to 14 days from the time, they're infected. (41).

There's no single effective treatment modality for viral conjunctivitis; still, use of frequent artificial gashes, antihistamines containing eye drops, or cold- compresses feel to palliate numerous of the clinical symptoms that are associated with this condition.(47,48) Topical and oral antiviral specifics don't appear to be useful.(47,48) In addition, antibiotic eye drops don't play a part in treating viral conjunctivitis and may indeed obscure the clinical picture by converting optical face toxin.(15,16) Other enterprises with using antibiotic drops include increased bacterial resistance and the possibility of spreading the complaint to the contralateral eye by cross-contamination through the infected bottles.(42).

Membranes or pseudomembranes may be hulled at the tear-beacon by using a brace of jeweler forceps or cotton tar after anesthetizing the optical face. This is done to palliate patient discomfort and help unborn scar conformation.

Monotherapy against viral conjunctivitis with Povidone-iodine 2 have been delved in a airman study. The authors discovered that topical administration of Povidone-iodine 2 four times a day for one week led to complete resolution of the complaint in three- diggings of the eyes. (49).

The American Academy of Ophthalmology suggests that topical corticosteroids play an important part in the treatment of conjunctivitis, but they should be used judiciously and with caution in named cases. (47) suggestions for steroid operation in viral conjunctivitis are membrane conformation and subepithelial infiltration associated with severe photophobia and dropped vision. Dragging the duration of adenoviral conjunctivitis, exacerbation of HSV keratitis, and an increase in intraocular pressure are the main adverse goods of magpie use of topical corticosteroids.

extension of viral slipping following monotherapy with corticosteroids has been reported;(50) still, combination curatives with corticosteroids and anti-infective agents (i.e., antibiotics) have proven to be effective in treating viral and bacterial conjunctivitis. (51,52)

Ophthalmic phrasings of PVP- I/ dexamethasone are extensively delved. PVP- I0.4/ dexamethasone0.1 suspense, PVP I1.0/ dexamethasone0.1, and PVP- I0.6/ dexamethasone0.1 have been used, and the results suggest that the combination curatives reduce patient symptoms and annihilate the contagion effectively. (29)

Ongoing phase 3, randomized, twice- masked, controlled studies will further clarify the efficacy and safety of combined PVP- I/ dexamethasone in adenoviral conjunctivitis (ClinicalTrials.gov identifiers NCT0299855441 and NCT0299854142) and bacterial conjunctivitis (ClinicalTrials.gov identifiers NCT03004924).

Use of 1 and 2 cyclosporine- A(CsA) eye drops have been supported for the treatment of SEIs, and it has been demonstrated to be effective in perfecting patient symptoms and reducing the quantities of infiltrates.(30,56) still, Jeng et al suggested that it might be delicate to wean cases fully off CsA once they've started it; in their study, when CsA was stopped, SEIs returned, challenging reinstatement of the CsA eye drops.(57) This finding is in discrepancy with the Reinhard's airman study, where no rush was observed after termination of the CsA drops.(58) In a small study conforming of 39 cases, administration of 1 cyclosporine- A(four times a day) during the acute phase of viral conjunctivitis and continuing it later for 21 days lowered the prevalence of corneal darkness significantly.(59) A case- controlled double-blindfolded randomized clinical trial is demanded to probe the effectiveness of cyclosporine- A and to formulate an ideal tapering troop for this drug.

The use of topical tacrolimus eye drops has also been delved for the treatment of SEIs secondary to adenoviral

keratoconjunctivitis. When tacrolimus eye drops or ointments were used for an normal of six months, a significant reduction in the size and figures of SEIs was observed in 60 of the cases, while in31.76 of the eyes, SEIs were excluded after one time. (60) There was also a statistically significant enhancement in the visual perceptivity of the cases with the use of topical tacrolimus.

G. Herpetic conjunctivitis

It's estimated that 1.3 –4.8 of all cases of acute conjunctivitis are caused by HSV infection. (61) HSV frequently causes a unilateral follicular conjunctivitis, which may be accompanied by a thin watery blasting and hooked up vesicular lesions on the skin of the eyelids. Treatment consists of topical antiviral agents, carrying ganciclovir, idoxuridine, vidarabine, and trifluridine. The aim of the treatment is to reduce contagion slipping and the chance of the development of keratitis.

optical involvement with herpes zoster contagion, especially when the first and alternate branches of the trigeminal whim-whams are involved, can lead to conjunctivitis in41.1 of cases, eyelid lesions in45.8, uveitis in38.2, and corneal lesions similar as SEIs, pseudodendrites, and nummular keratitis in another19.1. (64,65)

H. Acute hemorrhagic conjunctivitis

Acute hemorrhagic conjunctivitis (AHC) is an extremely pestilent form of viral conjunctivitis. It manifests by nonnative body sensation, gushing tearing, eyelid edema, dilatation of conjunctival vessels, chemosis, and subconjunctival hemorrhage. In a small proportion of cases, fever, fatigue, and leg pain may postdate. Two picornaviruses, videlicet enterovirus 70(EV70) and coxsackievirus A24 variant(CA24v), as well as certain subtypes of adenoviruses are believed to be the responsible pathogens.() Like the other forms of conjunctivitis, AHC is also believed to be transmitted primarily by hand- to- eye- to- hand contact and infected fomites.(69) The condition is tone- limited and the symptoms dwindle gradationally during the first week of infection and fully resolves after 10 – 14 days.(69) Medical intervention aims primarily at controlling the large outbreaks as well as constituting precautionary measures to cover the vulnerable groups, similar as children, senior, pregnant women, and immunocompromised individualities, by encouraging frequent handwashing and reducing contact with the affected individualities.(68)

I. eclectic viral conjunctivitis

Infection with Molluscum contagiosum (MC) is characterized by multiple umblicated and papular skin lesions caused by Spell- 2 contagion. Skin- to- skin connection and sexual interaction are the main routes of transmission. slipping of the viral proteins from the eyelid lesions into the gash film leads to habitual follicular conjunctival response, punctate keratopathy, and subepithelial pannus. Infrequently, primary MC lesions are set up in the conjunctiva. (70).

Ebola hemorrhagic fever is a fatal complaint caused by the

Table 3
Ophthalmic drug therapies for acute bacterial conjunctivitis.

Antibiotic agents	Treatment
Aminoglycosides	
Gentamicin	Ointment: 4 ×/d for 1 wk Solution: 1-2 drops 4 ×/d for 1 wk
Tobramycin	Ointment: 3 ×/d for 1 wk
Fluoroquinolones	
Besifloxacin	1 drop 3 ×/d for 1 wk
Ciprofloxacin	Ointment: 3 ×/d for 1 wk Solution: 1-2 drops 4 ×/d for 1 wk
Gatifloxacin	3 ×/d for 1 week
Levofloxacin	1-2 drops 4 ×/d for 1 wk
Moxifloxacin	3 ×/d for 1 wk
Ofloxacin	1-2 drops 4 ×/d for 1 wk
Macrolides	
Azithromycin	2 ×/d for 2 d; then 1 drop daily for 5 d
Erythromycin	4 ×/d for 1 wk
Sulfonamides	
Sulfacetamide	Ointment: 4 ×/d and at bedtime for 1 wk Solution: 1-2 drops every 2-3 h for 1 wk
Combination drops	
Trimethoprim/polymyxin B	1 or 2 drops 4 ×/d for 1 wk

species of ebolavirus. Conjunctival injection, subconjunctival hemorrhage, and tearing have been reported in the affected individualities. (71) Conjunctival injection, which is frequently bilateral and present in over to 58 of cases, has been linked in both the acute and late stages of this complaint and may play an important part in the early opinion of this potentially deadly condition. (72) While mortal- to- mortal transmission through fleshly fluids can spread the infection, the natural force is allowed to be the fruit club. (73).

Coronaviruses include a broad family of contagions that typically affect creatures, although some strains can spread from creatures to humans. (74) The most lately insulated strain of coronavirus, “2019- nCoV ”, has made the captions since it was first honored in December 2019 in China. COVID- 19 has been reported to beget fever, cough, briefness of breath, and indeed death. (75,76) Some reports have suggested that this contagion can beget conjunctivitis and be transmitted via the conjunctival concealment of the infected individualities (76) All healthcare professionals including the ophthalmologists should be watchful in approaching cases with conjunctivitis and respiratory symptoms, especially if they report a recent history of trip to high threat regions. (76)

J. Bacterial conjunctivitis

While in grown-ups, bacterial conjunctivitis is less common than viral conjunctivitis, in children, it's encountered more constantly. (77) Bacterial conjunctivitis can affect from either a direct contact with infected individualities or from abnormal proliferation of the native conjunctival foliage. (78) polluted fritters,(41) oculogenital spread,(47) and defiled fomites(79) are common routes of transmission. In addition, certain conditions similar as compromised gash product, dislocation of the natural epithelial hedge, abnormality of adnexal structures, trauma, and immunosuppressed status increase the liability of constricting bacterial conjunctivitis. (47)

Acute bacterial conjunctivitis is most frequently caused by Staphylococcus species, Haemophilus influenza, Streptococcus species, Moraxella catarrhalis, and gram-negative intestinal bacteria. (80) In youngish children, minor pandemics may do secondary toH. influenza orS. pneumonia. Acute bacterial conjunctivitis manifests by foreign body sensation and increased optical stashing in addition to moderate conjunctival hyperemia (Figure 4).

Several studies on bacterial conjunctivitis (81,82) demonstrate that sticky eyelids and itching may be present in roughly 90 of the affected individualities; these findings are followed by the less constantly encountered signs and symptoms similar as purulent stashing and optical burning.H. influenza conjunctivitis may be associated with acute otitis media and upper respiratory tract infection. (80).

In further than 60 of cases, robotic cure occurs within one – two weeks, (83) and serious complications are extremely rare. (84) still, presence of a large population of bacteria on the conjunctiva exposes the case to a advanced threat of keratitis, particularly in conditions associated with corneal epithelial blights, similar as dry eye. (80).

Although topical antibiotics reduce the duration of the complaint, no difference in the outgrowth is seen between the treatment and placebo groups. In a meta- analysis, (81), conforming of 3,673 cases from 11 randomized clinical trials, antibiotic treatment increased the rate of clinical enhancement by 10 compared to placebo. Both “2 to 5” and “6 to 10” day paratroops were included in this analysis. Although, largely malign bacteria can potentially induce serious damage to the optical face and the eye, (78), no sight- hanging complications were reported in any of the placebo groups in the forenamed meta- analysis. (85).

All broad- diapason antibiotic eye drops feel to be effective in treating bacterial conjunctivitis and it's doubtful that there's a significant difference among colorful antibiotics in achieving

clinical cure. Factors that impact antibiotic choice are original vacuity, patient disinclinations, resistance patterns, and cost.

From a large methodical review, it was concluded that topical antibiotics were more effective in achieving clinical and microbial cure when cases had positive bacterial societies. (21) still, no significant difference has been reported in clinical cure rate when different frequentness of the antibiotics was administered. [86,87] Due to lengthening the course of the illness and potentiating the infection, topical steroids should be avoided [47] (Table 3).




Fig.4. Thick purulent discharge in a patient with acute bacterial conjunctivitis

Seasonal and perennial allergic conjunctivitis	Vernal and atopic keratoconjunctivitis	Giant papillary conjunctivitis and contact dermatitis/conjunctivitis
<ul style="list-style-type: none"> Antihistamines, mast cell 		<ul style="list-style-type: none"> T cells, prostaglandins
<ul style="list-style-type: none"> Anti histamine, mast cell stabilizers 		<ul style="list-style-type: none"> Immunosuppressants (CS, cyclosporine)

Fig.5. Spectrum of allergic conjunctivitis. CS, corticosteroid




Fig.6. cobblestone appearance of large conjunctival papillae in a patient with VKC (left). Limbal VKC with Horner-Trantas dots in another patient (right).




Fig.7. Some systemic and dermatological conditions associated with conjunctivitis




Fig.8. Symblepharon formation in a patient with ocular cicatricial pemphigoid

K. Methicillin-resistant *S. aureus* conjunctivitis

The term methicillin-resistant *S. aureus* (MRSA) refers to *Staphylococcus aureus* species that are resistant to methicillin antibiotic; still, currently the term is used to describe resistance to all β -lactam antimicrobials. (88) Growing in frequency, 3 – 64 of all optical *Staphylococcus* conjunctival infections are MRSA conjunctivitis. (89) Suspected cases need to be treated with fortified vancomycin eye drops or ointments. (90) Culture-directed administration of antimicrobials, effective dosing, considering the original resistance patterns, and applicable antiseptic strategies should be applied to circumscribe the spread of MRSA conjunctivitis. (91)

L. Chlamydial conjunctivitis

Chlamydia trachomatis may beget a variety of optical face infections including trachoma, neonatal conjunctivitis, and addition conjunctivitis. Serotype D- K are causative agents for neonatal conjunctivitis and adult addition conjunctivitis, while trachoma is caused by serotypes A, B, Ba, and C. (92)

Addition conjunctivitis is reported to beget 1.8 – 5.6 of all cases of acute conjunctivitis, (93) where the maturity of cases are unilateral and have concurrent genital infection. (94) Cases frequently present with mild mucopurulent discharge and follicular conjunctivitis persisting for weeks to months. (77) Up to 54 of men and 74 of women are reported to have contemporaneous genital infection. (95) The complaint is constantly acquired via oculogenital spread. (47) Treatment with systemic antibiotics similar as oral azithromycin and doxycycline is efficient, while addition of topical antibiotics isn't salutary. Treatment of sexual mates and looking for the substantiation of coinfection with gonorrhea must be introduced.

As the leading cause of contagious blindness in the world, trachoma affects 40 million individualities worldwide; this infection is current in areas with poor hygiene. Although mucopurulent discharge is the original presenting sign, in the after stages, scarring of the eyelids, conjunctiva, and cornea may lead to loss of vision. A single cure of oral azithromycin (20 mg/ kg) in addition to oral tetracycline or erythromycin for three weeks is veritably effective. Cases may also be treated

with topical antibiotic ointments, similar as tetracycline and erythromycin, for six weeks. (96,97)

In babe, chlamydia can beget conjunctivitis following passage through an infected birth conduit. The acute phase, which generally begins between days 5 and 14 following vaginal delivery, is characterized by purulent discharge, erythema and edema of the eyelids and conjunctiva. (98) further current than gonococcal conjunctivitis (GC), neonatal conjunctivitis secondary to *C. trachomatis* is considered the most frequent contagious cause of neonatal conjunctivitis worldwide. (99)

Although the chlamydial conjunctivitis has a mild course, scarring of the cornea and/ or conjunctiva have been reported in undressed cases. (101) It's important to note that over to 20 of the babes who are exposed to chlamydia may develop pneumonia; in these, 50 demonstrate a former history of conjunctivitis. (102)

A recent meta- analysis supports the superiority of traditional treatment with systemic erythromycin at 50 mg/ kg per day(given in four divided boluses for two weeks), in comparison to topical antibiotic remedy alone.(103) A recent study assessing the efficacy of azithromycin in neonatal chlamydial conjunctivitis(104) demonstrated superiority of erythromycin over azithromycin; still, threat of pyloric stenosis related to the use of erythromycin may reduce its clinical use in babes in the future.(103) also, less-frequent cure of azithromycin may ameliorate compliance.(105)

M. *Gonococcal conjunctivitis (GC)*

Generally viewed as a condition affecting the babes, GC, still, affects other age groups as well. (106) *Neisseria gonorrhoeae* is a common cause of hyperacute conjunctivitis in babes and sexually active grown-ups. (78) optical infection with *N. gonorrhoea* is associated with a high frequency of corneal perforation. (80) GC should be considered as the causative agent in babes who present with conjunctivitis in days 2 to 5 after delivery. (106) In both neonatal and non-neonatal populations, eye test may reveal conjunctival injection and chemosis along with riotous mucopurulent discharge; a tender globe with periauricular lymphadenopathy may similarly be hobnobbed with this type of conjunctivitis. (106).

The suggested treatment for babes includes single cure of ceftriaxone (25 to 50 mg/ kg), or cefotaxime (100 mg/ kg IV or IM), in addition to hourly saline irrigation of the optical face. (107) Non-neonates can be treated with combination of 1 gm of IM ceftriaxone given in a single cure and 1 gm of oral azithromycin (which is used to treat the constantly encountered chlamydial coinfection). Irrigation of the optical face with saline result isn't necessary in grown-ups. (106)

N. *Antipathetic conjunctivitis*

optical dislike can affect the entire optical face including conjunctiva, eyelids, and cornea. According to the immunological medium responsible for the final clinical picture, Leonardi et al have classified optical antipathetic

conditions into three main orders(109) IgE- intermediated responses, including seasonal antipathetic conjunctivitis(SAC) and imperishable antipathetic conjunctivitis(PAC); combined IgE and non-IgE-mediated responses, including VKC and AKC; and non-IgE-mediated responses, including giant papillary conjunctivitis(GPC) and contact dermatitis conjunctivitis(CDC)(Figure 5).

Seasonal antipathetic conjunctivitis (SAC) and imperishable antipathetic conjunctivitis (PAC)

SAC and PAC are considered as the most current antipathetic optical conditions, affecting 15 – 20 of the population. (110) The pathogenesis is generally an IgE- intermediated acuity response, and allergen-specific IgE antibodies are set up in nearly all cases of SAC and PAC.(111) Activation of mast cells contributes to increased situations of histamine, prostaglandins, and leukotrienes in the gash film. This phase, which is known as the ancient reaction phase, clinically lasts 20 – 30min. (8)

SAC, also known as hay fever conjunctivitis, is seen in all age groups. The optical instantiations do generally during the spring and summer months when pollens from the trees and shops are released into the air. PAC on the other hand can do throughout the time with exposure to more common allergens similar as beast hair, diminutives, and feathers. (112) Clinical signs and symptoms are analogous in SAC and PAC, and include itching and burning of the eyes, tearing, and rhinorrhea. Corneal involvement is infrequently seen. (9)

O. *Vernal keratoconjunctivitis (VKC)*

VKC is known as the complaint of youthful males who live in warmer climates. (113,114) Although VKC is constantly diagnosed in children, grown-ups can also be affected with this condition. (115) A admixture of IgE and non-IgE response in response to nonspecific stimulants, similar as wind, dust, and sun is frequently illustrated in this condition. Consequently, skin tests and serum IgE antibody tests to well- known allergens are generally negative. (116) Both clinical and histological findings support the attendant part of T- coadjutor 2 and IgE in the pathogenesis of VKC. (8,117) lately, IL- 17 has been reported to be linked to VKC, where its serum situations can serve as a marker for the inflexibility of the complaint. (118,119) High chance of antinuclear antibodies (Corpus) positivity and family history of autoimmune diseases in cases with VKC suggests a strong link between this condition and other autoimmune diseases including atopy. (120,121).

Typical seasonal patterns as well as imperishable forms have been reported in cases affected with VKC. (122) Presence of papillary hyperplasia is essential for the opinion of VKC, and its presence allows for the isolation of VKC from other affiliated realities similar as SAC and PAC. (123)

Conjunctival injection, gushing tearing, severe itching, and photophobia are the main clinical signs and symptoms that are associated with VKC. There are three clinical forms of VKC that include limbal, palpebral, and mixed type. (112) Limbal type is characterized by limbal papillary response and glutinous

thickening of the limbus; when the complaint is active, Horner-Trantas blotches are generally present at the superior limbal perimeters. (112) The hallmark of the palpebral VKC is the presence of giant papillae, with consequent cobblestone appearance. The mixed type has the features of palpebral and limbal VKC contemporaneously (Figure 6).

The corneal pathology that's seen in VKC is incompletely caused by the mechanical trauma from the tarsal conjunctival papillae and the seditious responses secondary to the release of cytokines. The seditious intercessors are believed to be released by the eosinophils and mast cells that are sneaked into the conjunctival towel. (124,125) In up to 6 of cases, corneal ulcers (i.e., securities ulcer) and pillars may develop, leading to the exacerbation of the clinical symptoms and worsening of the vision. (126,127) These ulcers are generally set up as round lesions with elevated perimeters girding a habitual epithelial disfigurement covered by eosinophilic and epithelial debris in the upper corridor of the cornea. (128) Keratoconus is another reality that's largely associated with VKC affecting nearly 15 of the cases with this condition. (129)

P. Atopic keratoconjunctivitis (AKC)

AKC is characterized by habitual antipathetic complaint of the eyelid, cornea, and conjunctiva. It's considered the optical element of atopic dermatitis (announcement), and roughly 95 of the cases with AKC have attendant announcement; (8,11) still, lower than half of cases with announcement have involvement of their optical towel. (130) numerous cytokines are released from the epithelial cells of the conjunctiva as well as the seditious cells that have sneaked the conjunctival apkins in AKC. This causes constant redoing of the optical face connective towel leading to mucus metaplasia, scar conformation, and corneal neovascularization. (131).

AKC is generally diagnosed in the alternate and third decades of life, although scattered cases are seen in the early nonage as well as in the fifth decade of life. (132) Age of the onset, duration of the complaint, and clinical donations may help clinicians to distinguish this condition from VKC (132).

Clinical incarnation of AKC includes epiphora, itching, greenishness, and dropped vision. donation is frequently bilateral; still, unilateral complaint has been reported. (133) The eyelid skin may be edematous with a sandpaper- suchlike texture. Conjunctival injection and chemosis range from mild to severe, and conjunctival scarring is common. (11) Trantas blotches and giant papillae may or may not be present. In discrepancy to VKC, AKC is associated with conjunctival fibrosis and corneal vascularization and darkness. An early cataract surgery isn't uncommon in AKC cases, as this condition is associated with conformation of "atopic cataracts" at a fairly youthful age. Shield- suchlike cataracts, as well as nuclear, cortical and indeed posterior subcapsular cataracts may also do. Nearly 50 of AKC cases test negative for common allergens. (8).

Q. Giant papillary conjunctivitis (GPC)

analogous to vernal conjunctivitis, GPC is characterized by papillary hypertrophy of the superior tarsal conjunctiva. (34) Although GPC is primarily considered as a complication of contact lens operation, this condition has also been reported in association with corneal foreign bodies, filtering blebs, optical prostheses, exposed sutures, limbal dermoids, and towel bonds. (36) The classic signs of GPC correspond of inordinate mucous stashing associated with dropped contact lens forbearance. (137) Mast cells and eosinophils may be set up in the conjunctiva; still, there are no increases in the situations of IgE or histamines in the gashes of cases with GPC. (8).

GPC can do with both hydrogel and rigid contact lenses, and it has been reported with either hydroxyethyl methacrylate (HEMA), silicone polymers, or the new gas passable polymers. (134) still, it's lower frequent with rigid contact lenses. Mechanical injuries due to contact lens wear and tear and seditious responses secondary to face proteins of the lens can contribute to the habitual seditious damage of the optical face (110,138) seen in this condition.

R. Contact mislike

CDC is a classic illustration of type- IV delayed acuity response that occurs through commerce of antigens with T cells followed by release of cytokines. (139) Low molecular weight allergens combine with host proteins to form the final allergens able of plying vulnerable response. Some of the known allergens for CDC include bane ivy, bane oak, neomycin, nickel, latex, atropine and its derivations. (8) Primary sensitization phase describes the process through which memory T cells decide from occupant T cells of the optical towel, while the following elicitation phase includes the commerce between these memory cells and allergens. (8) IL-17-producing Th cells and nonsupervisory T cells also play a part in the pathogenesis of CDC. (140)

analogous to AKC, contact mislike involves the conjunctiva, cornea, and eyelids. The condition may be associated with itching, lid lump, follicular response, and indeed cicatrization in after stages of the complaint. The corneal involvement may be in the form of punctate keratitis, pseudodendritic keratitis, and gray stromal infiltrates. (112,141)

S. Treatment

Avoidance of the allergens is the main stay of treatment for numerous forms of disinclinations including antipathetic conjunctivitis. Artificial gashes give a hedge function, dilute colorful allergens, and flush the optical face clean from numerous seditious intercessors.

The treatment options for antipathetic conjunctivitis include slicking eye drops, anti-histamines, and mast cell stabilizers. (142,143) numerous studies have demonstrated the superiority of topical antihistamines and mast cell stabilizers compared to placebo in easing the symptoms of antipathetic conjunctivitis; in addition, it has been demonstrated that antihistamines are more salutary than mast cell stabilizers for furnishing short-

term relief. (144) Several eye drop medications with binary action (antihistamine and mast cell- stabilizing goods) including olopatadine, ketotifen, azelastine, and epinastine have been introduced to request in the recent times. These agents can give contemporaneous histamine receptor antagonist goods, stabilize mast- cell membranes, and modify the action of eosinophils. (145) Mast cell stabilizers bear a lading period of several weeks, and thus, they're better to be administered before the antigen exposure.

Oral antihistamines are generally used for easing the optical symptoms in cases with antipathetic conjunctivitis. Alternate generation antihistamines are preferred due to their smaller adverse systemic side goods. (146) Unfortunately, oral antihistamines induce optical drying, which can significantly worsen the symptoms of antipathetic conjunctivitis. (147)

Steroids should be used judiciously and only in named cases. Topical and oral administration, in addition to supratarsal injections are frequently needed if the condition is severe; unfortunately, any route of corticosteroid administration is associated with conformation of cataracts and elevated intraocular pressure. (112) Non-steroidal anti-inflammatory medicines similar as ketorolac and diclofenac can also be added to the treatment authority to give fresh benefits. also, other steroid- sparing agents similar as cyclosporine- A and tacrolimus are effective in treating severe and habitual forms of optical disinclinations.

Allergen-specific immunotherapy, which has gained fashionability in the recent times, works by converting clinical forbearance to a specific allergen. This appears to be an effective treatment options for those with antipathetic rhinoconjunctivitis who demonstrate specific IgE antibodies. (148) Traditionally, immunotherapy is performed via subcutaneous injections; still, sublingual immunotherapy (tear) has drawn the attention among allergists as volition. tear has been shown to effectively reduce the optical and nasal signs and symptoms of antipathetic conjunctivitis, with a lesser benefit toward perfecting the nasal symptoms. (112)

T. *Conjunctivitis associated with systemic*

Conjunctivitis may be the original donation for numerous systemic conditions; thus, a thorough history and systemic evaluation in named cases may help in early opinion of numerous potentially disabling and indeed life-changing conditions. A summary of systemic conditions associated with conjunctivitis is handed in Figure 7.

1) *Reactive arthritis*

Conjunctivitis is one of the most common optical instantiations of reactive arthritis; other associated optical realities include uveitis, episcleritis, scleritis, and keratitis. (149) Conjunctivitis in reactive arthritis realities manifests itself as conjunctival hyperemia with purulent discharge. being in nearly one third of the cases, conjunctivitis is an essential element of the "Reiter's trio". (150) Conjunctivitis generally happens early in the course of reactive arthritis and it may indeed antecede it in some cases; given its mild original clinical

donation, it's frequently missed. The signs and symptoms generally abate within one to four weeks; still, in some cases, progression to more severe optical face problems may postdate. (151)

2) *Rosacea*

Ocular face may also be involved in the seditious course of optical rosacea. The clinical findings include a follicular and papillary conjunctival response in association with interpalpebral conjunctival hyperemia. In addition, cicatrization of the conjunctival towel, mimicking trachoma, may be seen in these cases. Conjunctival scarring secondary to entropion and trichiasis has been reported to do in roughly 10 of the cases. Conjunctival granuloma, pinguecula, phlyctenule, and supplemental corneal infiltration and phlyctenule are amongst some of the other findings associated with optical rosacea. (152)

3) *Graft- versus- host disease*

Conjunctival involvement is infrequently seen in acute graft-versus- host complaint (GVHD); still, its presence indicates more severe systemic involvement and a poor prognostic. Conjunctival involvement in GVHD ranges from mild conjunctival injection to pseudomembranous and cicatrizing conjunctivitis. (153,154) In acute GVHD, conjunctivitis is frequently ulcerative and manifests itself with multitudinous interspersing occurrences of conjunctival hemorrhage and exudative discharge. Sterile purulent discharge, pseudomembrane conformation, and scarring are amongst the other findings in this condition. (153) In the habitual form of GVHD, one- fourth to three- fourth of the cases suffer from dry eyes, where its inflexibility correlates with the inflexibility of GVHD. (155) constantly, keratoconjunctivitis sicca persists after absolution of GVHD. (156)

Four stages of conjunctival GVHD have been set out in the literature. Stage 1 is labeled by plain conjunctival injection. Stage 2 is defined by an exudative reply, which may lead to conjunctival chemosis. Stage 3 is characterized by pseudomembrane conformation; maturity of the cases is diagnosed at this stage of the conditions. Stage 4 is manifested by scarring and cicatrization of the conjunctival towel. (153,156)

optical cicatricial pemphigoid optical cicatricial pemphigoid is a rare condition. Cases are frequently in their fifth and sixth decades of life at donation, and ladies are over to three times more constantly affected than males. (157) habitual inflammation, loss of conjunctival tableware cells along with an abnormal mucosal epithelial turn- over leads to desiccation of the optical face in this condition (158) (Figure 8). dislocation of conjunctival vulnerable network increases the threat of optical face infection. (158) intermittent contagious conjunctivitis and trichiasis may lead to keratinization of the face epithelium. (158) Definitive opinion requires direct immunofluorescence, where deposits of immunoglobulins and/ or complements produce areas of direct hyperfluorescence at the epithelial basement membrane. Systemic immunosuppression along with frequent lubrication is frequently demanded to adequately

control this condition.

U. Stevens- Johnson pattern and poisonous epidermal necrolysis

Ophthalmic instantiations of the acute stages of Stevens-Johnson pattern (SJS) and poisonous epidermal necrolysis (TEN) range from conjunctival hyperemia to near-complete sloughing of palpebral conjunctiva and lid perimeters. (159) Acute optical involvement is reported to do in over to 88 of the cases. (159) It remains unclear whether the inflexibility of optical involvement is any different between SJS and TEN. (160) Long- term adverse consequences following the acute stage of optical face complaint include severe dry eyes, symblepharon conformation, corneal limbal stem cell insufficiency, and corneal scarring. (160)

1) Toxic conjunctivitis

It has been lately realized that long- term use of topical eye specifics may induce optical face changes including dry eyes, conjunctival inflammation, optical face fibrosis, and scarring. (161,162) Another area where the side goods of topical eye drops cause significant optical morbidity is their use in glaucoma and in cases who have experienced glaucoma surgery. Subclinical infiltration of the conjunctival epithelium and substantia propria by seditious cells has also been reported. (163,164) The published literature during the once decade has refocused to the injurious goods of benzalkonium chloride (BAK), which is used as a preservative in eye drops, on the optical face. (165).

Antipathetic responses are the most clinically conspicuous side effect of the eye drops; still, they're far less frequent and dangerous than their adverse poisonous side goods. (166) The antipathetic response to eye drops includes simple conjunctival traffic, papillary conjunctivitis, and GPC. (165) The signs and symptoms generally manifest a many days after starting the offending eye drop and tend to resolve snappily when the drug is stopped. (166)

experimental studies have verified the high frequency of dry eyes in glaucoma cases related to the number of eye drops being used. This ranges from 11 in those who use only one eye drop to 43 in those who use two or three different eye drops. (167) also, across-sectional study assessing the optical face in 101 cases being treated for glaucoma reported that roughly 60 of them were characteristic in at least one eye. (168) In a check performed on 300 cases in the US between 2001 and 2004, adverse side goods were reported to be the alternate most common reason for switching eye drops. (169)

Increase in fibroblast viscosity in the conjunctiva, and development of subconjunctival fibrosis has been reported in cases who use antiglaucoma drops chronically. (165) In a series of 145 cases, Thorne et al recited that openness to antiglaucoma eye drops was the immediate reason for development of pseudomemphigoid. (170)

Despite the irrefutable data and the findings from multiple experimental studies on the dangerous side goods of BAK, it's still used as the main preservative component in utmost eye

drop medications due to lack of a better volition. (165) Limiting the exposure to preservatives may dwindle the poisonous side goods of eye drops; this will probably lead to advanced patient compliance and affect in a more favorable clinical outgrowth, especially in those who need to be on antiglaucoma specifics.

3. Conclusion

Roughly 1 of all patient visits to their primary care croaker is conjunctivitis related, and the estimated cost of contagious conjunctivitis to the healthcare is further than \$ 800 million annually in the US alone. (2) The first step in approaching a case with presumed conjunctivitis is to rule out serious optical conditions that present with "red eye", mimicking conjunctivitis. This must be done with carrying a thorough history and performing a detailed ophthalmologic and physical examination. Ancillary laboratory testing and imaging are also important factors of assessing these cases. colorful studies have demonstrated that carrying a thorough history is essential to constrict down the discriminational opinion and discover the underpinning etiology for the conjunctivitis, while counting solely on the presenting signs and symptoms can be deceiving and frequently leads to an inaccurate opinion. Viral conjunctivitis followed by bacterial conjunctivitis are the most common causes of contagious conjunctivitis. (26) The maturity of viral conjunctivitis cases is due to adenoviruses, (28) and the use of rapid-fire antigen test to diagnose adenoviral conjunctivitis may present an applicable strategy to avoid overuse of antibiotics. Bacterial pathogens are insulated in half of the cases of conjunctivitis, (61) and roughly 60 of culture-positive cases are known to be tone- limited. (80) societies should be attained from the conjunctival hearties of cases that don't respond to remedy, and those suspected to have chlamydial infection and hyperacute conjunctivitis. (47) Treatment with topical antibiotics is generally recommended for suspected cases of chlamydial and gonococcal conjunctivitis and contact lens wear and tear. (61,80) The maturity of cases of antipathetic conjunctivitis are due to seasonal disinclinations. Antihistamines and mast cell stabilizers are extensively used for treating antipathetic conjunctivitis. Steroids must be applied judiciously and only when indicated. For cases with habitual conjunctivitis, possibility of systemic conditions and adverse goods of eye drops with preservatives should be kept in mind.

References

- [1]. Shekhawat NS, Shtein RM, Blachley TS, Stein JD. Antibiotic prescription fills for acute conjunctivitis among enrollees in a large United States managed care network. *Ophthalmology* 2017; 124:1099–1107.
- [2]. Smith AF, Waycaster C. Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. *BMC Ophthalmol* 2009; 9:13.
- [3]. Ryder EC, Benson S. *Conjunctivitis*. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2020.

- [4]. de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1. *Orphanet J Rare Dis* 2013; 8:8–8.
- [5]. Sati A, Sangwan VS, Basu S. Porphyria: varied ocular manifestations and management. *BMJ Case Rep* 2013;2013: bcr2013009496.
- [6]. Narayana S, McGee S. Bedside diagnosis of the 'Red Eye': a systematic review. *Am J Med* 2015; 128:1220–1224.e1221.
- [7]. Everitt H, Little P. How do GPs diagnose and manage acute infective conjunctivitis? A GP surveys. *Fam Pract* 2002; 19:658–660.
- [8]. La Rosa M, Lionetti E, Reibaldi M, et al. Allergic conjunctivitis: a comprehensive review of the literature. *Ital J Pediatr* 2013; 39:18.
- [9]. Friedlaender MH. Ocular allergy. *Curr Opin Allergy Clin Immunol* 2011; 11:477–482.
- [10]. Bielory L, Frohman LP. Allergic and immunologic disorders of the eye. *J Allergy Clin Immunol* 1992; 89:1–15.
- [11]. Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. *Immunol Allergy Clin North Am* 2010; 30:323–336.
- [12]. Wilson-Holt N, Dart JK. Thiomersal keratoconjunctivitis, frequency, clinical spectrum and diagnosis. *Eye* 1989; 3:581–587.
- [13]. Soparkar CN, Wilhelmus KR, Koch DD, Wallace GW, Jones DB. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. *Arch Ophthalmol* 1997; 115:34–38.
- [14]. van Ketel WG, Melzer-van Riemsdijk FA. Conjunctivitis due to soft lens solutions. *Contact Dermatitis* 1980; 6:321–324.
- [15]. Woodland RM, Darougar S, Thaker U, Cornell L, Siddique M, Wania J, et al. Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan. *Trans Royal Soc Trop Med Hygiene* 1992; 86:317–320.
- [16]. Bielory BP, O'Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. *Acta Ophthalmologica* 2012; 90:399–407.
- [17]. Rietveld RP, van Weert HC, ter Riet G, Bindels PJ. Diagnostic impact of signs and symptoms in acute infectious conjunctivitis: systematic literature search. *BMJ* 2003; 327:789.
- [18]. Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. *BMJ* 2004; 329:206–210.
- [19]. Jefferis J, Perera R, Everitt H, van Weert H, Rietveld R, Glasziou P, et al. Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis. *Br J Gen Pract* 2011;61: e542–548.
- [20]. van Weert HC, Tellegen E, Ter Riet G. A new diagnostic index for bacterial conjunctivitis in primary care. A re-derivation studies. *Eur J Gen Pract* 2014; 20:202–208.
- [21]. Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. *JAMA* 2013; 310:1721–1729.
- [22]. Drew RJ, Cole TS, Newman W. How to use... eye swabs. *Arch Dis Child Educ Pract Ed* 2015; 100:155–161.
- [23]. Wong VW, Lai TY, Chi SC, Lam DS. Pediatric ocular surface infections: a 5-year review of demographics, clinical features, risk factors, microbiological results, and treatment. *Cornea* 2011; 30:995–1002.
- [24]. Kam KY, Ong HS, Bunce C, Ogunbowale L, Verma S. Sensitivity and specificity of the AdenoPlus point-of-care system in detecting adenovirus in conjunctivitis patients at an ophthalmic emergency department: a diagnostic accuracy study. *Br J Ophthalmol* 2015; 99:1186–1189.
- [25]. Stenson S, Newman R, Fedukowicz H. Laboratory studies in acute conjunctivitis. *Arch Ophthalmology* 1982; 100:1275–1277.
- [26]. Fitch CP, Rapoza PA, Owens S, Murillo-Lopez F, Johnson RA, Quinn TC, et al. Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital. *Ophthalmology* 1989; 96:1215–1220.
- [27]. Newman H, Gooding C. Viral ocular manifestations: a broad overview. *Rev Med Virol* 2013; 23:281–294.
- [28]. O'Brien TP, Jeng BH, McDonald M, Raizman MB. Acute conjunctivitis: truth and misconceptions. *Curr Med Res Opin* 2009; 25:1953–1961.
- [29]. Singh G, Zhou X, Lee JY, Yousuf MA, Ramke M, Ismail AM, et al. Recombination of the epsilon determinant and corneal tropism: human adenovirus species D types 15, 29, 56, and 69. *Virology* 2015;485:452–459.
- [30]. Kuo IC. Adenoviral keratoconjunctivitis: diagnosis, management, and prevention. *Curr Ophthalmol Rep* 2019; 7:118–127.
- [31]. Li J, Lu X, Sun Y, Lin C, Li F, Yang Y, et al. A swimming pool-associated outbreak of pharyngoconjunctival fever caused by human adenovirus type 4 in Beijing, China. *Int J Infect Dis* 2018; 75:89–91.
- [32]. Harley D, Harrower B, Lyon M, Dick A. A primary school outbreak of pharyngoconjunctival fever caused by adenovirus type 3. *Comm Dis Intell* 2001; 25:9–12.
- [33]. Sinclair RG, Jones EL, Gerba CP. Viruses in recreational water-borne disease outbreaks: a review. *J Appl Microbiol* 2009; 107:1769–1780.
- [34]. Darougar S, Grey RH, Thaker U, McSwiggan DA. Clinical and epidemiological features of adenovirus keratoconjunctivitis in London. *Br J Ophthalmol* 1983; 67:1–7.
- [35]. Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB. Adenoviral keratoconjunctivitis. *Surv Ophthalmol* 2015; 60:435–443.
- [36]. Chintakuntlawar AV, Chodosh J. Cellular and tissue architecture of conjunctival membranes in epidemic keratoconjunctivitis. *Ocul Immunol Inflamm* 2010; 18:341–345.
- [37]. Chigbu DI, Labib BA. Pathogenesis and management of adenoviral keratoconjunctivitis. *Infect Drug Resist* 2018; 11:981–993.

- [38]. Richmond S, Burman R, Crosdale E, et al. A large outbreak of keratoconjunctivitis due to adenovirus type 8. *The Journal of hygiene* 1984; 93:285-291.
- [39]. Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A, et al. Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis. *BMC Ophthalmol* 2012; 12:42.
- [40]. Ghanem RC, Vargas JF, Ghanem VC. Tacrolimus for the treatment of subepithelial infiltrates resistant to topical steroids after adenoviral keratoconjunctivitis. *Cornea* 2014; 33:1210–1213.
- [41]. Gallenga PE, Lobefalo L, Colangelo L, Della Loggia G, Orzalesi N, Velati P, et al. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: a multicenter double-blind phase III study. *Ophthalmologica* 1999; 213:250–257.
- [42]. Udeh BL, Schneider JE, Ohsfeldt RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. *Am J Med Sci* 2008; 336:254–264.
- [43]. Jackson WB, Low DE, Dattani D, Whitsitt PF, Leeder RG, MacDougall R. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. *Can J Ophthalmol* 2002; 37:228–237; discussion 237.
- [44]. Gordon YJ, Gordon RY, Romanowski E, Araullo-Cruz TP. Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. *Ophthalmology* 1993; 100:1835–1839; discussion 1839–1840.
- [45]. Junk AK, Chen PP, Lin SC, Nouri-Mahdavi K, Radhakrishnan S, Singh K, et al. Disinfection of Tonometers: a report by the American Academy of Ophthalmology. *Ophthalmology* 2017; 124:1867–1875.
- [46]. Bremond-Gignac D, Mariani-Kurkdjian P, Beresniak A, El Fekih L, Bhagat Y, Pouliquen P, et al. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. *Pediatr Infect Dis J* 2010; 29:222–226.
- [47]. Varu DM, Rhee MK, Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, et al. Conjunctivitis preferred practice pattern®. *Ophthalmology* 2019;126: P94–P169.
- [48]. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. *Am J Ophthalmol* 1991; 112:29s–33s.
- [49]. Trinavarat A, Atchaneeyasakul LO. Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study. *J Ocul Pharmacol Ther* 2012; 28:53–58.
- [50]. Kovalyuk N, Kaiserman I, Mimouni M, Cohen O, Levartovsky S, Sherbany H, et al. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. *Acta Ophthalmol* 2017;95: e686–e692.
- [51]. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. *Cornea* 2008; 27:50–55.
- [52]. Belfort R, Jr., Gabriel L, Martins Bispo PJ, Muccioli C, Zacharias Serapicos PC, Clark L, et al. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. *Adv Ther* 2012; 29:416–426.
- [53]. Clement C, Capriotti JA, Kumar M, et al. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. *Investigative ophthalmology & visual science* 2011; 52:339-344.
- [54]. Pinto RD, Lira RP, Abe RY, Fernandes Felix JP, Fernandes Pereira AV, Leite Arieta CE, et al. Dexamethasone/povidone eye drops versus artificial tears for treatment of presumed viral conjunctivitis: a randomized clinical trial. *Curr Eye Res* 2015; 40:870–877.
- [55]. Pepose JS, Ahuja A, Liu W, Narvekar A, Haque R. Randomized, controlled, phase 2 trial of povidone-iodine/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis. *Am J Ophthalmol* 2019; 205:197.
- [56]. Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR. Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. *Cornea* 2010; 29:638–640.
- [57]. Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis. *Cornea* 2011; 30:958–961.
- [58]. Reinhard T, Godehardt E, Pfahl HG, Sundmacher R. [Local cyclosporin A in nummuli after keratoconjunctivitis epidemica. a pilot study]. *Ophthalmologie* 2000; 97:764–768.
- [59]. Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Carlsburg O, Roggendorf M, et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. *Arch Ophthalmol* 2001; 119:1487–1491.
- [60]. Berisa Prado S, Riestra Ayora AC, Lisa Fernandez C, Chacon Rodriguez M, Merayo-Llodes J, Alfonso Sanchez JF. Topical tacrolimus for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. *Cornea* 2017; 36:1102–1105.
- [61]. Cronau H, Kankanala RR, Mauger T. Diagnosis and management of red eye in primary care. *Am Fam Phys* 2010; 81:137–144.
- [62]. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. *Cochrane Database Syst Rev* 2012;19: Cd001211.
- [63]. Papa V, Aragona P, Scuderi AC, Blanco AR, Zola P, Alessandro Di B, et al. Treatment of acute bacterial conjunctivitis with topical netilmicin. *Cornea* 2002; 21:43–47.

- [64].Puri LR, Shrestha GB, Shah DN, Chaudhary M, Thakur A. Ocular manifestations in herpes zoster ophthalmicus. *Nepal J Ophthalmol* 2011; 3:165–171.
- [65].Sy A, McLeod SD, Cohen EJ, Margolis TP, Mannis MJ, Lietman TM, et al. Practice patterns and opinions in the management of recurrent or chronic herpes zoster ophthalmicus. *Cornea* 2012; 31:786–790.
- [66].Lim KH, Yin-Murphy M. Epidemic conjunctivitis in Singapore in 1970 and 1971. *Singapore Med J* 1973; 14:86–89.
- [67].Kono R, Sasagawa A, Miyamura K, Tajiri E. Serologic characterization and sero-epidemiologic studies on acute hemorrhagic conjunctivitis (AHC) virus. *Am J Epidemiol* 1975; 101:444–457.
- [68].Zhang L, Zhao N, Huang X, Jin X, Geng X, Chan T-C, et al. Molecular epidemiology of acute hemorrhagic conjunctivitis caused by coxsackie a type 24 variant in China, 2004–2014. *Sci Rep* 2017; 7:45202.
- [69].Langford MP, Anders EA, Burch MA. Acute hemorrhagic conjunctivitis: anti-coxsackievirus A24 variant secretory immunoglobulin A in acute and convalescent tear. *Clin Ophthalmol* 2015; 9:1665–1673.
- [70].Serin S, Bozkurt Oflaz A, Karabagli P, Gedik S, Bozkurt B. Eyelid molluscum contagiosum lesions in two patients with unilateral chronic conjunctivitis. *Turk J Ophthalmol* 2017; 47:226–230.
- [71].Breman JG, Heymann DL, Lloyd G, McCormick JB, Miatudila M, Murphy FA, et al. Discovery and description of ebola zaire virus in 1976 and relevance to the West African epidemic during 2013–2016. *J Infect Dis* 2016;214: S93–S101.
- [72].Moshirfar M, Fenzl CR, Li Z. What we know about ocular manifestations of Ebola. *Clin Ophthalmol* 2014; 8:2355–2357.
- [73].Bausch DG, Schwarz L. Outbreak of ebola virus disease in Guinea: where ecology meets economy. *PLoS Negl Trop Dis* 2014;8: e3056–e3056.
- [74].Peiris JS, Lai ST, Poon LL, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003; 361:1319–1325.
- [75].Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395: P497–P506.
- [76].Karimi S, Arabi A, Shahraki T, Safi S. Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with Coronavirus disease 2019. *Eye*. Retrieved from: 10.1038/s41433-020-0965-2.
- [77].Epling J. Bacterial conjunctivitis. *BMJ Clin Evid* 2012; 2012:0704.
- [78].Shields T, Sloane PD. A comparison of eye problems in primary care and ophthalmology practices. *Fam Med* 1991; 23:544–546.
- [79].Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. *Clin Ther* 2009; 31:514–526.
- [80].Hovding G. Acute bacterial conjunctivitis. *Acta Ophthalmol* 2008; 86:5–17.
- [81].Horven I. Acute conjunctivitis. A comparison of fusidic acid viscous eye drops and chloramphenicol. *Acta Ophthalmol* 1993; 71:165–168.
- [82].Wall AR, Sinclair N, Adenis JP. Comparison of fucithalamic (fusidic acid viscous eyedrops 1%) and noroxin (norfloxacin ophthalmic solution 0.3%) in the treatment of acute bacterial conjunctivitis. *J Drug Assess* 1998; 1:549–558.
- [83].Rose PW, Harnden A, Brueggemann AB, Perera R, Sheikh A, Crook D, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. *Lancet* 2005; 366:37–43.
- [84].Schiebel NE. Evidence-based emergency medicine/systematic review abstract. Use of antibiotics in patients with acute bacterial conjunctivitis. *Ann Emer Med* 2003; 41:407–409.
- [85].Gong L, Sun XH, Qiu XD, Zhang Y-Q, Qu J, Yuan Z-l, et al. [Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes]. [*Zhonghua yan ke za zhi*] *Chinese J Ophthalmol* 2010; 46:525–531.
- [86].Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. *Curr Med Res Opin* 2009; 25:1159–1169.
- [87].Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MB. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. *Br J Ophthalmol* 2003; 87:1004–1009.
- [88].Shanmuganathan VA, Armstrong M, Buller A, Tullo AB. External ocular infections due to methicillin-resistant *Staphylococcus aureus* (MRSA). *Eye* 2005; 19:284–291.
- [89].Zhang M, Hu Y, Chen F. [Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis]. *Yan Ke Xue Bao [Eye Sci]* 2000; 16:146–148.
- [90].Gross RD, Lichtenstein S, Schlech BA, Gower LA, Potts SL. Early clinical and microbiological responses in the treatment of bacterial conjunctivitis with moxifloxacin ophthalmic solution 0.5% (Vigamox™) using B.I.D. dosing. *Today Ther Trends* 2003; 21:227–237.
- [91].Thareja T, Kowalski R, Jhanji V, Kamyar R, Dhaliwal D. MRSA keratitis and conjunctivitis: what does it mean practically? *Curr Ophthalmol Rep* 2019; 7:110–117.
- [92].Burton MJ. Trachoma: an overview. *Br Med Bull* 2007; 84:99–116.
- [93].Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial

- conjunctivitis. *J Pediatr Ophthalmol Strabismus* 2008; 45:340–349.
- [94].Leibowitz HM. The red eye. *New Engl J Med* 2000; 343:345–351.
- [95].Tabbara KF, El-Sheikh HF, Islam SM, Hammouda E. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%. *Eur J Ophthalmol* 1999; 9:269–275.
- [96].Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. *Am J Ophthalmol* 2008; 145:959–965.
- [97].Cochereau I, Meddeb-Ouertani A, Khairallah M, Amraoui A, Zaghoul K, Pop M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. *Br J Ophthalmol* 2007; 91:465–469.
- [98].Darville T. Chlamydia trachomatis infections in neonates and young children. *Semin Pediatr Infect Dis* 2005; 16:235–244.
- [99].Mallika P, Asok T, Faisal H, Aziz S, Tan A, Intan G. Neonatal conjunctivitis - a review. *Malays Fam Phys* 2008; 3:77–81.
- [100].Castro Ochoa KJ, Mendez MD. Ophthalmia Neonatorum. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing LLC; 2020.
- [101].Forster RK, Dawson CR, Schachter J. Late follow-up of patients with neonatal inclusion conjunctivitis. *Am J Ophthalmol* 1970; 69:467–472.
- [102].Tipple MA, Beem MO, Saxon EM. Clinical characteristics of the afebrile pneumonia associated with Chlamydia trachomatis infection in infants less than 6 months of age. *Pediatrics* 1979; 63:192–197.
- [103].Zikic A, Schunemann H, Wi T, Lincetto O, Broutet N, Santesso N. Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis. *J Pediatr Infect Dis Soc* 2018;7: e107–e115.
- [104].Hammerschlag MR, Gelling M, Roblin PM, Kutlin A, Jule JE. Treatment of neonatal chlamydial conjunctivitis with azithromycin. *Pediatr Infect Dis J* 1998; 17:1049–1050.
- [105].Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. *Patient Prefer Adherence* 2013; 7:419–434.
- [106].Costumbrado J, Ng DK, Ghassemzadeh S. Gonococcal conjunctivitis. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2020.
- [107].Hammerschlag MR, Smith-Norowitz T, Kohlhoff SA. Keeping an eye on Chlamydia and gonorrhoea conjunctivitis in infants in the United States, 2010–2015. *Sex Transm Dis* 2017; 44:577.
- [108].Pak KY, Kim SI, Lee JS. Neonatal bacterial conjunctivitis in Korea in the 21st century. *Cornea* 2017; 36:415–418.
- [109].Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. *Curr Opin Allergy Clin Immunol* 2007; 7:429–435.
- [110].Wong AH, Barg SS, Leung AK. Seasonal and perennial allergic conjunctivitis. *Recent Pat Inflamm Allergy Drug Discov* 2014; 8:139–153.
- [111].Bonini S. Atopic keratoconjunctivitis. *Allergy* 2004; 59:71–73.
- [112].Rathi VM, Murthy SI. Allergic conjunctivitis. *Commun Eye Health* 2017;30: S7–S10.
- [113].Sofi RA, Mufti A. Vernal keratoconjunctivitis in Kashmir: a temperate zone. *Int Ophthalmol* 2016; 36:875–879.
- [114].Katelaris CH. Ocular allergy in the Asia Pacific region. *Asia Pac Allergy* 2011; 1:108–114.
- [115].De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. *Br J Ophthalmol* 2013; 97:9–14.
- [116].Jun J, Bielory L, Raizman MB. Vernal conjunctivitis. *Immunol Allergy Clin North Am* 2008; 28:59–82.
- [117].Zicari AM, Capata G, Nebbioso M, De Castro G, Midulla F, Leonardi L, et al. Vernal keratoconjunctivitis: an update focused on clinical grading system. *Ital J Pediatr* 2019; 45:64.
- [118].Zicari AM, Nebbioso M, Zicari A, Mari E, Celani C, Occasi F, et al. Serum levels of IL-17 in patients with vernal keratoconjunctivitis: a preliminary report. *Eur Rev Med Pharmacol Sci* 2013; 17:1242–1244.
- [119].Validad MH, Khazaei HA, Pishjoo M, Safdari Z. The study of Interleukin-17 levels in vernal keratoconjunctivitis disease and its relationship between symptom and sign severity. *Sem Ophthalmol* 2017; 32:721–724.
- [120].Occasi F, Zicari AM, Petrarca L, Nebbioso M, Salvatori G, Duse M. Vernal keratoconjunctivitis and immune-mediated diseases: one unique way to symptom control? *Pediatr Allergy Immunol* 2015; 26:289–291.
- [121].Zicari AM, Nebbioso M, Lollobrigida V, Bardanzellu F, Celani C, Occasi F, et al. Vernal keratoconjunctivitis: atopy and autoimmunity. *Eur Rev Med Pharmacol Sci* 2013; 17:1419–1423.
- [122].Singhal D, Sahay P, Maharana PK, Raj N, Sharma N, Titiyal JS. Vernal keratoconjunctivitis. *Surv Ophthalmol* 2019; 64:289–311.
- [123].Pucci N, Novembre E, Lombardi E, Cianferoni A, Bernardini R, Massai C, et al. Atopy and serum eosinophil cationic protein in 110 white children with vernal keratoconjunctivitis: differences between tarsal and limbal forms. *Clin Exp Allergy* 2003; 33:325–330.
- [124].Kumagai N, Fukuda K, Fujitsu Y, Yamamoto K, Nishida T. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. *Prog Retin Eye Res* 2006; 25:165–187.
- [125].Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. *Allergy* 2012; 67:1327–1337.

- [126].Solomon A. Corneal complications of vernal keratoconjunctivitis. *Curr Opin Allergy Clin Immunol* 2015; 15:489–494.
- [127].Cameron JA, Mullaney PB. Amblyopia resulting from shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. *J Pediatr Ophthalmol Strabismus* 1997; 34:261–262.
- [128].Cameron JA. Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. *Ophthalmology* 1995; 102:985–993.
- [129].Totan Y, Hepsen IF, Cekic O, Gunduz A, Aydin E. Incidence of keratoconus in subjects with vernal keratoconjunctivitis: a videokeratographic study. *Ophthalmology* 2001; 108:824–827.
- [130].Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. *Curr Opin Allergy Clin Immunol* 2010; 10:478–485.
- [131].Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? *Curr Opin Allergy Clin Immunol* 2009; 9:477–481.
- [132].Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: a review. *J Am Acad Dermatol* 2014; 70:569–575.
- [133].Li A, Li S, Ruan F, Jie Y. Atopic keratoconjunctivitis: a diagnostic dilemma—a case report. *Medicine* 2018;97: e0372.
- [134].Elhers WH, Donshik PC. Giant papillary conjunctivitis. *Curr Opin Allergy Clin Immunol* 2008; 8:445–449.
- [135].Forister JF, Forister EF, Yeung KK, Ye P, Chung MY, Tsui A, et al. Prevalence of contact lens-related complications: UCLA contact lens study. *Eye Contact Lens* 2009; 35:176–180.
- [136].Vengayil S, Vanathi M, Dada T, Kai S, Panda A. Filtering bleb-induced giant papillary conjunctivitis. *Cont Lens Anterior Eye* 2008; 31:41–43.
- [137].Elhers W, Donshik P. Giant papillary conjunctivitis. *Curr Opin Allergy Clin Immunol* 2008; 8:445–449.
- [138].Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. *Immunol Allergy Clin North Am* 2008; 28:83–103.
- [139].Niederhorn JY. Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models. *Curr Opin Allergy Clin Immunol* 2008; 8:472–476.
- [140].Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. *Allergol Int* 2008; 57:121–134.
- [141].Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. *Eye* 2003; 17:886–892.
- [142].Schmid KL, Schmid LM. Ocular allergy: causes and therapeutic options. *Clin Exp Optom* 2000; 83:257–270.
- [143].Gokhale NS. Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. *Indian J Ophthalmol* 2016; 64:145–148.
- [144].Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. *Br J Gen Pract* 2004; 54:451–456.
- [145].Mishra GP, Tamboli V, Jwala J, Mitra AK. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. *Recent Pat Inflamm Allergy Drug Discov* 2011; 5:26–36.
- [146].Maziak W, Behrens T, Brasky TM, Duhme H, Rzehak P, Weiland SK, et al. Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Munster, Germany. *Allergy* 2003; 58:572–579.
- [147].Welch D, Ousler GW, 3rd, Nally LA, Abelson MB, Wilcox KA. Ocular drying associated with oral antihistamines (loratadine) in the normal population—an evaluation of exaggerated dose effect. *Adv Exp Med Biol* 2002; 506:1051–1055.
- [148].Broide DH. Immunomodulation of allergic disease. *Ann Rev Med* 2009; 60:279–291.
- [149].Szamocki S, Martyn-Hemphill C, Green J. Reactive arthritis: can't see, can't pee, can't climb a tree.... *Trends Urol Men Health* 2016; 7:17–20.
- [150].Keat A. Reiter's syndrome and reactive arthritis in perspective. *New Engl J Med* 1983; 309:1606–1615.
- [151].Hamdulay SS, Glynne SJ, Keat A. When is arthritis reactive? *Postgrad Med J* 2006; 82:446–453.
- [152].Faraj HG, Hoang-Xuan T. Chronic cicatrizing conjunctivitis. *Curr Opin Ophthalmol* 2001; 12:250–257.
- [153].Jabs DA, Wingard J, Green WR, Farmer ER, Vogelsang G, Saral R. The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. *Arch Ophthalmol* 1989; 107:1343–1348.
- [154].Azari A, Rezaei Kanavi M, Potter H, Hematti P. Autologous serum eye drop is safe and effective for treatment of dry eyes in graft-versus-host disease. *Invest Ophthalmol Vis Sci* 2013; 54:4330–4330.
- [155].Tabbara KF, Al-Ghamdi A, Al-Mohareb F, Ayas M, Chaudhri N, Al-Sharif f, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. *Ophthalmology* 2009; 116:1624–1629.
- [156].Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus-host disease. *Saudi J Ophthalmol* 2013; 27:215–222.
- [157].Bedell AJ. Ocular pemphigus: a clinical presentation of kodachromes. *Trans Am Ophthalmol Soc* 1964; 62:109–122.
- [158].Wang K, Seitzman G, Gonzales JA. Ocular cicatricial pemphigoid. *Curr Opin Ophthalmol* 2018; 29:543–551.
- [159].Kohanin S, Palioura S, Saeed HN, et al. Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis - a comprehensive review and guide to therapy. II. Ophthalmic disease. *Ocul Surf* 2016; 14:168–188.
- [160].Chow LLW, Shih KC, Chan JCY, Lai JSM, Ng ALK. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. *BMC Ophthalmol* 2017; 17:65.

- [161].Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. *Br J Ophthalmol* 1993; 77:590–596.
- [162].Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. *Ophthalmology* 1992; 99:197–202.
- [163].Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. *Graefes Arch Clin Exp Ophthalmol* 1994; 232:561–565.
- [164].Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. *Ophthalmology* 1999; 106:556–563.
- [165].Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. *Prog Retin Eye Res* 2010; 29:312–334.
- [166].Baudouin C. Allergic reaction to topical eyedrops. *Curr Opin Allergy Clin Immunol* 2005; 5:459–463.
- [167].Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. *Eur J Ophthalmol* 2009; 19:572–579.
- [168].Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. *J Glaucoma* 2008; 17:350–355.
- [169].Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. *J Ocul Pharmacol Ther* 2009; 25:145–152.
- [170].Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. *Ophthalmology* 2004; 111:45–52.